Skip to content
OpenCapital
Get started

Mesa Laboratories MLAB Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%

Other financials

Income statement

See full
Revenue$63.7M+2.6%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$3.6M+317%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$26.9M-1.4%
Total debt$78.7M-53.1%
Total equity$186.2M+16.5%
Total assets$427.7M-1.3%

Cash flow

See full
Operating cash flow$14.0M+10.2%
CapEx$417.0K-44.9%
Free cash flow$13.5M+13.7%

Valuation

See full
Market cap$542.27M+3.7%
Enterprise value$594.05M-10.4%
P/S2.2×0.0×

Profitability

See full
Gross margin56.8%—
Operating margin2.3%—
Net margin1.5%+0.8pp
FCF margin15.9%-1.8pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.7×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Mesa Laboratories’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Mesa Laboratories's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mesa Laboratories's increase (decrease) in contract liabilities and current deferred income?
Mesa Laboratories (MLAB) reported increase (decrease) in contract liabilities and current deferred income of -$813K in Q3 2025.
How has Mesa Laboratories's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Mesa Laboratories's increase (decrease) in contract liabilities and current deferred income decreased by 108.5% year-over-year, from -$390K to -$813K.